Treatment of progressive prostatic cancer after local therapy


Cite item

Full Text

Abstract

About the authors

A V Morozov

References

  1. Amling С. L., Bergstralh E. J., Brute M. L. et al. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J. Urol. (Baltimore) 2001; 165: 1146-1151.
  2. Moul J. W. Prostate specific antigen only progression of prostate cancer. J. Urol. (Baltimore) 2000; 163: 1632-1642.
  3. Critz F. A., Williams W. H., Benton J. B. et al. Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer. J. Urol. (Baltimore) 2000; 163: 1085-1089.
  4. Crawford E. D. Patient selection for therapy in prostate cancer. Eur. Urol. 2002; suppl. 1: 2-6.
  5. Pound С. R., Partin A. W., Epstein J. I., Walsh P. С. Prostate specific antigen after anatomic radical retropubic prostatectomy Patterns of recurrence and cancer control. Urol. Clin. N. Am. 1997; 24: 395-406.
  6. Small E. J., Roach III M. Prostate-specific antigen in prostate cancer: a case study in the development of a tumour marker to monitor recurrence and assess response. Semin. Oncol. 2002; 29 (3): 264-273.
  7. Anderson J. В., Fourcade R. O., Payne H. A., Sculman Cl. С. How do we deal with rising PSA after primary therapy? Eur. Urol. 2002; suppl. 1: 33-38.
  8. Han M., Partin A. W., Pound С. R. et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol. Clin. N. Am. 2001; 28: 555-565.
  9. Wirth M., Iversen P., Mcleod D., See W. Immediate therapy in early prostate cancer: results from the Bicalutamide ("Casodex") EPC program. Eur. Urol. 2002; suppl. 1: 20-25.
  10. Petrovitch Z., Lieskovsky G., Stein J. P. et al. Comparison of surgery alone with surgery and adjuvant radiotherapy for PT3No prostate cancer. Br. J. Urol. Int. 2002; 89: 604-611.
  11. Bolla M. Treatment of localized or local advanced prostate cancer: the clinical use of radiotherapy. EAU Update Ser. 1 2003; 23-31.
  12. Cox J. D., Gallagher M. J., Hammond E. H. et al. Consensus statement on radiation therapy of prostate cancer: guidelines for prostate rebiopsy after radiation and for radiation therapy with rising prostate-specific antigen level after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. J. Clin. Oncol. 1999; 17: 1155.
  13. Матвеев Б. П., Бухаркин Б. В., Матвеев В. Б. Рак предстательной железы. М.: ИЧП Фирма "Рича"; 1999.
  14. Shekarriz В., Upadhyay J., Pontes J. E. Salvage radical prostatectomy. Urol. Clin. N. Am. 2001; 28: 545-553.
  15. Messing E. M., Manola J., Sarosdy M. et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N. Engl. J. Med. 1999; 341: 1781-1788.
  16. Aus G., Abramsson P. A., Ahlgren G. et al. Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial. Br. J. Urol. Int. 2002; 90: 561-566.
  17. Soloway M. S., Pareek K., Sharifi R. et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J. Urol. (Baltimore) 2002; 167: 112-116.
  18. Fitzpatrick J. M., Don Newling, Vela-Navarrete R. Experience in advanced and metastatic prostatic cancer. Eur. Urol. 2002; suppl. 1: 39-44.
  19. Iversen P. Current topics in the treatment of hormone-refractory prostate cancer. Eur. Urol. 2003; suppl. 2: 3-8.
  20. See W. A., Wirth M. P., Mcleod D. G. et al. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: rirst analysis of the early prostate cancer program. J. Urol. (Baltimore) 2002; 168: 429-435.
  21. Hanks G. E., Lu J., Machtay M. et al. RTOG Protocol 92-02: a phase III trial of the use of long term androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of prostate. Proc. Am. Soc Oncol. 2000; 19: 327a [abstr. 1284].
  22. Lawton С. A., Winter K., Murray K. et al. Update results of the phase III Radiation Therapy Oncology Group (RTOG) Trial 85-31 evaluating the potential benefit of androden suppression folloing standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 2001; 49: 937-946.
  23. Pilepich M. V., Winter K., John M. J. et al. Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int. J. Radiol. Oncol. Biol. Phys. 2001; 50: 1243-1252.
  24. Prapotnich D., Fizazi K., Escudier B. et al. A 10-year clinical experience with intermittent hormonal therapy for prostate cancer. Eur. Urol. 2003; 43: 233-240.
  25. Bruchovsky N., Klotz I. H., Sadar M. Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observation. Mol. Urol. 2000; 4: 191-199.
  26. Buchler K. R., Santucci R. A., Royai R. A. et al. Intermittent androgen suppression in the LuCaP 23.12 prostate cancer xenograft model. Prostate 2000; 43 (1): 63-70.
  27. Gross/eld G. D., Chaudary U. В., Reese D. M. et al. Intermittent androgen deprivation: update of cycling characteristics in patients without clinically apparent metastatic prostate cancer. Urology 2001; 58 (2): 240-245.
  28. Smith D. C., Redman B. G., Flaherty L. E. et al. A phase II trial of oral diethylstilbestrol as a second-line hormonal agent in advanced prostate cancer. Urology 1998; 52: 257-260.
  29. Acosta S., Abrahamsson P. A. Somatostatin analogue treatment of patient with hormone refractory prostate cancer: first clinical results. Eur. Urol. 2001; 39 (suppl. 5): 80 [abstr. 309].
  30. Koutsillieris M., Mitsiadis C., Dimopulos T. et al. A combination therapy of dexamethasone and somatostatine analog reintroduces objective clinical responses to LHRH analog in androgen ablation refractory prostate cancer patients. J. Clin. Endocrinol. Metab. 2001; 86: 5729-5736.
  31. Bok R. A., Small E. J. The Treatment of advanced prostate cancer with ketoconazole: safety issues. Drug Saf. 1999; 20: 451-458.
  32. Chay С. H., Smith D. C. Fardig J. et al. Phase II trial of paclitaxel, estramustine, etoposide and carboplatin (TEEC) in treatment of hormone-refractory prostate cancer. Proc. Am. Soc. Clin. Oncol. 2001; 20 (171b): [abstr. 2435].
  33. Kelly W. K., Curley Т., Slovin S. et al. Paclitaxel, estramustine phosphate and carboplatin in patients with advanced prostate cancer. J. Clin. Oncol. 2001; 19: 44-53.
  34. Smith D. C., Esper P., Strawderman M. et al. Phase II trial of oral estramustine, oral etoposide, and intravenouse paclitaxel in hormone-refractory prostate cancer. J. Clin. Oncol. 1999; 17: 1664-1671.
  35. Savarese D. V., Halabi S., Hars V. et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: A final report of CALGB 9780 Cancer and Leukemia Group B. J. Clin. Oncol. 2001; 19: 2509-2516.
  36. Petrylak D. P. Chemotherapy for treatment of hormone-refractory prostate cancer. Eur. Urol. 2002; suppl. 1: 15-23.
  37. Kish J. A., Bukkapatnam R., Palazzo F. The treatment challenge of hormone-refractory prostate cancer. Cancer Control 2001; 8: 487-495.
  38. Manni A., Bartholomew M., Caplan R. et al. Androgen priming and chemotherapy in advanced prostate cancer: evaluation of clinical outcome. J. Clin. Oncol. 1988; 6: 1456-1466.
  39. Bubley G. J., Carducci M., Dahut W. et al. Eligibility and response guidelines for phase II clinic trials in androgen-independent prostate cancer: recommendation from the prostate-specific antigen working group. J. Clin. Oncol. 1999; 17: 3461-3467.
  40. Heidenreich A., von Knobloch R., Hoffmann R. Current status of cytotoxic chemotherapy in hormonal refractory prostate cancer. Eur. Urol. 2001; 39: 121-130.
  41. Pummer K. The role of urologists in the management of hormonerefractory prostate cancer. Enrol. Urol. 2002; suppl. 1: 24-28.
  42. Saad F., Schulman С. С. Role of biphosphonates in prostate cancer. Eur. Urol. 2004; 45: 26-34.
  43. Carrol P. R., Benaron D. A., Blackledge G. et al. Third international conference on innovation and challenges in prostate cancer: prevention, detection and treatment. J. Urol. (Baltimore) 2003; 170: S3-S5.
  44. Smith M. R. Biphosphonates to prevent skeletal complications in men with metastatic prostate cancer. J. Urol. (Baltimore) 2003; 170: S55-S58.
  45. Higano С. S. Management of bone loss in men with prostate cancer. J. Urol. (Baltimore) 2003; 170: S59-S64.
  46. Heidenreich A., Elert A., Hoffmann R. Ibandronate in the treatment of prostate cancer assosiated painful osseus metastases. Prostate Cancer Prostate Dis. 2002; 5: 231-235.
  47. Muhlbauer R. S. BM 21.0955, a potent new biphosphonate to inhibit bone resorption. J. Done Miner. Res. 1991; 6: 1003-1011.
  48. Heidenreich A., Schroder A. J. The treatment of hormone-refractory prostate cancer. EAU Update Ser. 1, 2003; 40-50.
  49. Trachtenberg J. Emerging pharmacological therapies for prostate cancer. Rev. Urol. 2001; 3 (suppl. 3): S23-S28.
  50. Trachtenberg J., Blackledge G. Looking to the future: advances in the management of hormone-refractory prostate cancer. Eur. Urol. 2002; suppl. 1: 44-53.
  51. Zellweger Т., Miyake H., Chi K. et al. Targeting cell survival genes using antisense oligonucleotides to improve chemo- and hormonal-therapies in prostate cancer. Eur. Urol. 2002; suppl. 1: 7-14.
  52. Schulman C.I. Atrasentan: the first endothelin receptor antagonist for hormone-refractory prostate cancer. Eur. Urol. 2003; suppl. 2: 20-27.
  53. Nelson J. B. Endothelin inhibition: novel therapy for prostate cancer. J. Urol. (Baltimore) 2003; 170: S65-S68.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2005 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies